May 26, 2022

Nurix

Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development

May 25, 2022

Terremoto Biosciences

Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines

May 19, 2022

Voyager Therapeutics

Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs

May 18, 2022

Ambys Medicines

Ambys Medicines Presents New Data Further Validating its Novel Liver Cell Replacement Therapy Platform at the ASGCT Annual Meeting

May 17, 2022

Nurix

Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas

Load More

Sign up for weekly portfolio news.